151 related articles for article (PubMed ID: 34461615)
21. Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion.
Cekiç O; Chang S; Tseng JJ; Barile GR; Weissman H; Del Priore LV; Schiff WM; Weiss M; Klancnik JM
Retina; 2005; 25(7):846-50. PubMed ID: 16205562
[TBL] [Abstract][Full Text] [Related]
22. Effects of Intravitreal Ranibizumab Injection on Peripheral Retinal Microcirculation and Cytokines in Branch Retinal Vein Occlusion with Macular Edema.
Yasuda K; Noma H; Mimura T; Nonaka R; Sasaki S; Suganuma N; Shimura M
Medicina (Kaunas); 2023 May; 59(6):. PubMed ID: 37374257
[No Abstract] [Full Text] [Related]
23. Changes in Retinal Microcirculation After Intravitreal Ranibizumab Injection in Eyes With Macular Edema Secondary to Branch Retinal Vein Occlusion.
Fukami M; Iwase T; Yamamoto K; Kaneko H; Yasuda S; Terasaki H
Invest Ophthalmol Vis Sci; 2017 Feb; 58(2):1246-1255. PubMed ID: 28241312
[TBL] [Abstract][Full Text] [Related]
24. Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion.
Yiu G; Welch RJ; Wang Y; Wang Z; Wang PW; Haskova Z
Ophthalmol Retina; 2020 Jan; 4(1):67-76. PubMed ID: 31669329
[TBL] [Abstract][Full Text] [Related]
25. Comparison of ranibizumab and subthreshold micropulse laser in treatment of macular edema secondary to branch retinal vein occlusion.
Buyru Özkurt Y; Akkaya S; Aksoy S; Şimşek MH
Eur J Ophthalmol; 2018 Nov; 28(6):690-696. PubMed ID: 29696993
[TBL] [Abstract][Full Text] [Related]
26. Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study.
Larsen M; Waldstein SM; Priglinger S; Hykin P; Barnes E; Gekkieva M; Das Gupta A; Wenzel A; Monés J;
Ophthalmol Retina; 2018 Feb; 2(2):134-142. PubMed ID: 31047340
[TBL] [Abstract][Full Text] [Related]
27. COMBINATION THERAPY OF INTRAVITREAL RANIBIZUMAB AND SUBTHRESHOLD MICROPULSE PHOTOCOAGULATION FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION: 6-MONTH RESULT.
Terashima H; Hasebe H; Okamoto F; Matsuoka N; Sato Y; Fukuchi T
Retina; 2019 Jul; 39(7):1377-1384. PubMed ID: 29689025
[TBL] [Abstract][Full Text] [Related]
28. Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.
Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; King J; Antoszyk AN; Peters MA; Tolentino M;
JAMA Ophthalmol; 2017 Jun; 135(6):639-649. PubMed ID: 28492860
[TBL] [Abstract][Full Text] [Related]
29. The short-term efficacy of intravitreal ranibizumab, aflibercept and dexamethasone implant in the treatment of macular edema due to non-ischemic central retinal vein occlusion.
Yucel OE; Birinci H; Sullu Y
Int Ophthalmol; 2019 Apr; 39(4):891-901. PubMed ID: 29550932
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
[TBL] [Abstract][Full Text] [Related]
31. Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion.
Kim M; Yu SY; Kim ES; Bae SH; Park JH; Yu HG; Kwak HW
Ophthalmologica; 2012; 227(3):132-8. PubMed ID: 22212151
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of intravitreal ziv-aflibercept in patients with macular edema following retinal vein occlusion in Korle-Bu Teaching Hospital, Ghana: a retrospective case series.
Braimah IZ; Agyabeng K; Amoaku WM
Int Ophthalmol; 2021 Jul; 41(7):2445-2453. PubMed ID: 33782846
[TBL] [Abstract][Full Text] [Related]
33. Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.
Chatziralli I; Theodossiadis G; Moschos MM; Mitropoulos P; Theodossiadis P
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1093-1100. PubMed ID: 28214955
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion.
Hoeh AE; Ach T; Schaal KB; Scheuerle AF; Dithmar S
Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1635-41. PubMed ID: 19633982
[TBL] [Abstract][Full Text] [Related]
35. Predictors of visual recovery in patients with macular edema secondary to central retinal vein occlusion after treatment with Conbercept.
Zhang Q; Hou Y; Cao X; Zhang R; Liu Y; Wei C; Wu C; Mei L; Zhang P
BMC Ophthalmol; 2021 Nov; 21(1):402. PubMed ID: 34809591
[TBL] [Abstract][Full Text] [Related]
36. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions.
Pieramici DJ; Rabena M; Castellarin AA; Nasir M; See R; Norton T; Sanchez A; Risard S; Avery RL
Ophthalmology; 2008 Oct; 115(10):e47-54. PubMed ID: 18708258
[TBL] [Abstract][Full Text] [Related]
37. Changes in Ocular Blood Flow after Ranibizumab Intravitreal Injection for Diabetic Macular Edema Measured Using Laser Speckle Flowgraphy.
Toto L; Evangelista F; Viggiano P; Erroi E; D'Onofrio G; Libertini D; Porreca A; D'Aloisio R; Mariacristina P; Di Antonio L; Di Nicola M; Mastropasqua R
Biomed Res Int; 2020; 2020():9496242. PubMed ID: 32104710
[TBL] [Abstract][Full Text] [Related]
38. Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes.
Ozkaya A; Tarakcioglu HN; Tanir I
Optom Vis Sci; 2018 Dec; 95(12):1149-1154. PubMed ID: 30451802
[TBL] [Abstract][Full Text] [Related]
39. Combination of Ranibizumab with macular laser for macular edema secondary to branch retinal vein occlusion: one-year results from a randomized controlled double-blind trial.
Song S; Yu X; Zhang P; Gu X; Dai H
BMC Ophthalmol; 2020 Jun; 20(1):241. PubMed ID: 32560639
[TBL] [Abstract][Full Text] [Related]
40. The influence of anti-VEGF therapy on present day management of macular edema due to BRVO and CRVO: a longitudinal analysis on visual function, injection time interval and complications.
Papadia M; Misteli M; Jeannin B; Herbort CP
Int Ophthalmol; 2014 Dec; 34(6):1193-201. PubMed ID: 25245600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
